ozuriftamab vedotin + pembrolizumab + evalstotug

A combination therapy consisting of **ozuriftamab vedotin** (CAB-ROR2-ADC), **pembrolizumab**, and **evalstotug** is under clinical investigation for the treatment of advanced solid tumors, including squamous cell carcinoma of the head and neck (SCCHN) and other malignancies. - **Ozuriftamab vedotin** is an antibody-drug conjugate targeting ROR2, a receptor tyrosine kinase associated with poor prognosis and therapy resistance, delivering a cytotoxic payload (monomethyl auristatin E) to tumor cells. - **Pembrolizumab** is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor. - **Evalstotug** is a conditionally active anti-CTLA-4 monoclonal antibody designed for tumor-microenvironment restricted activity, reducing systemic immune toxicity and enhancing tolerability in combination regimens. This combination leverages direct tumor targeting (ozuriftamab vedotin), immune system activation (pembrolizumab), and further immune regulation (evalstotug) for synergistic antitumor effect[1][3][5][6].